Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Durect Eyes Phase III In Alcoholic Hepatitis Despite Phase IIb Miss

Executive Summary

Durect thinks its epigenetic modulator shows promise with data showing reduction in 90-day mortality despite missing the primary endpoint of mortality and liver transplant rate.

You may also be interested in...



Italy’s Alfasigma Comes Calling After Intercept’s Cruel Summer

The Bologna-based firm is looking to grow its presence in the US as well as in gastrointestinal and liver disease as it acquires Intercept, which received a second rejection for its NASH drug OCA in June.

Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks

Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.

Tarsus Demonstrates Lotilaner’s Potential In Preventing Lyme Disease

Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel